Cargando…
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with bio...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295690/ https://www.ncbi.nlm.nih.gov/pubmed/34307404 http://dx.doi.org/10.3389/fmed.2021.668173 |
_version_ | 1783725486647541760 |
---|---|
author | Vitale, Antonio Obici, Laura Cattalini, Marco Lopalco, Giuseppe Merlini, Giampaolo Ricco, Nicola Soriano, Alessandra La Torre, Francesco Verrecchia, Elena Insalaco, Antonella Dagna, Lorenzo Jaber, Masen Abdel Montin, Davide Emmi, Giacomo Ciarcia, Luisa Barneschi, Sara Parronchi, Paola Ruscitti, Piero Maggio, Maria Cristina Viapiana, Ombretta Sota, Jurgen Gaggiano, Carla Giacomelli, Roberto Sicignano, Ludovico Luca Manna, Raffaele Renieri, Alessandra Lo Rizzo, Caterina Frediani, Bruno Rigante, Donato Cantarini, Luca |
author_facet | Vitale, Antonio Obici, Laura Cattalini, Marco Lopalco, Giuseppe Merlini, Giampaolo Ricco, Nicola Soriano, Alessandra La Torre, Francesco Verrecchia, Elena Insalaco, Antonella Dagna, Lorenzo Jaber, Masen Abdel Montin, Davide Emmi, Giacomo Ciarcia, Luisa Barneschi, Sara Parronchi, Paola Ruscitti, Piero Maggio, Maria Cristina Viapiana, Ombretta Sota, Jurgen Gaggiano, Carla Giacomelli, Roberto Sicignano, Ludovico Luca Manna, Raffaele Renieri, Alessandra Lo Rizzo, Caterina Frediani, Bruno Rigante, Donato Cantarini, Luca |
author_sort | Vitale, Antonio |
collection | PubMed |
description | Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers. Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbations was 458.2 flare/100 patients-year during the 12 months prior to the start of biologic treatment and 65.7 flare/100 patients-years during the first 12 months of therapy (p < 0.0001). The median duration of attacks was 5.00 (IQR = 10.50) days at the start of biologics and 1.00 (IQR = 0.00) days at the 12-month assessment (p < 0.0001). Likewise, a significant reduction was observed in the Autoinflammatory Disease Activity Index during the study period (p < 0.0001). A significant corticosteroid sparing effect was observed as early as the first 12 months of treatment both in the number of patients requiring corticosteroids (p = 0.025) and in the dosages employed (p < 0.0001). A significant reduction was identified in the erythrocyte sedimentation rate (p < 0.0001), C reactive protein (p < 0.0001), serum amyloid A (p < 0.0001), and in the 24-h proteinuria dosage during follow-up (p = 0.001). A relapsing-remitting disease course (OR = 0.027, C.I. 0.001–0.841, p = 0.040) and the frequency of relapses at the start of biologics (OR = 0.363, C.I. 0.301–0.953, p = 0.034) were significantly associated with a complete response. No serious adverse events were observed. Conclusions: Treatment with biologic agents is highly effective in controlling clinical and laboratory TRAPS manifestations. Patients with a relapsing-remitting course and a lower frequency of flares at the start of treatment show more likely a complete response to biologic agents. |
format | Online Article Text |
id | pubmed-8295690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82956902021-07-23 Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network Vitale, Antonio Obici, Laura Cattalini, Marco Lopalco, Giuseppe Merlini, Giampaolo Ricco, Nicola Soriano, Alessandra La Torre, Francesco Verrecchia, Elena Insalaco, Antonella Dagna, Lorenzo Jaber, Masen Abdel Montin, Davide Emmi, Giacomo Ciarcia, Luisa Barneschi, Sara Parronchi, Paola Ruscitti, Piero Maggio, Maria Cristina Viapiana, Ombretta Sota, Jurgen Gaggiano, Carla Giacomelli, Roberto Sicignano, Ludovico Luca Manna, Raffaele Renieri, Alessandra Lo Rizzo, Caterina Frediani, Bruno Rigante, Donato Cantarini, Luca Front Med (Lausanne) Medicine Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers. Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbations was 458.2 flare/100 patients-year during the 12 months prior to the start of biologic treatment and 65.7 flare/100 patients-years during the first 12 months of therapy (p < 0.0001). The median duration of attacks was 5.00 (IQR = 10.50) days at the start of biologics and 1.00 (IQR = 0.00) days at the 12-month assessment (p < 0.0001). Likewise, a significant reduction was observed in the Autoinflammatory Disease Activity Index during the study period (p < 0.0001). A significant corticosteroid sparing effect was observed as early as the first 12 months of treatment both in the number of patients requiring corticosteroids (p = 0.025) and in the dosages employed (p < 0.0001). A significant reduction was identified in the erythrocyte sedimentation rate (p < 0.0001), C reactive protein (p < 0.0001), serum amyloid A (p < 0.0001), and in the 24-h proteinuria dosage during follow-up (p = 0.001). A relapsing-remitting disease course (OR = 0.027, C.I. 0.001–0.841, p = 0.040) and the frequency of relapses at the start of biologics (OR = 0.363, C.I. 0.301–0.953, p = 0.034) were significantly associated with a complete response. No serious adverse events were observed. Conclusions: Treatment with biologic agents is highly effective in controlling clinical and laboratory TRAPS manifestations. Patients with a relapsing-remitting course and a lower frequency of flares at the start of treatment show more likely a complete response to biologic agents. Frontiers Media S.A. 2021-07-08 /pmc/articles/PMC8295690/ /pubmed/34307404 http://dx.doi.org/10.3389/fmed.2021.668173 Text en Copyright © 2021 Vitale, Obici, Cattalini, Lopalco, Merlini, Ricco, Soriano, La Torre, Verrecchia, Insalaco, Dagna, Jaber, Montin, Emmi, Ciarcia, Barneschi, Parronchi, Ruscitti, Maggio, Viapiana, Sota, Gaggiano, Giacomelli, Sicignano, Manna, Renieri, Lo Rizzo, Frediani, Rigante and Cantarini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Vitale, Antonio Obici, Laura Cattalini, Marco Lopalco, Giuseppe Merlini, Giampaolo Ricco, Nicola Soriano, Alessandra La Torre, Francesco Verrecchia, Elena Insalaco, Antonella Dagna, Lorenzo Jaber, Masen Abdel Montin, Davide Emmi, Giacomo Ciarcia, Luisa Barneschi, Sara Parronchi, Paola Ruscitti, Piero Maggio, Maria Cristina Viapiana, Ombretta Sota, Jurgen Gaggiano, Carla Giacomelli, Roberto Sicignano, Ludovico Luca Manna, Raffaele Renieri, Alessandra Lo Rizzo, Caterina Frediani, Bruno Rigante, Donato Cantarini, Luca Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network |
title | Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network |
title_full | Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network |
title_fullStr | Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network |
title_full_unstemmed | Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network |
title_short | Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network |
title_sort | biotechnological agents for patients with tumor necrosis factor receptor associated periodic syndrome—therapeutic outcome and predictors of response: real-life data from the aida network |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295690/ https://www.ncbi.nlm.nih.gov/pubmed/34307404 http://dx.doi.org/10.3389/fmed.2021.668173 |
work_keys_str_mv | AT vitaleantonio biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT obicilaura biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT cattalinimarco biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT lopalcogiuseppe biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT merlinigiampaolo biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT ricconicola biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT sorianoalessandra biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT latorrefrancesco biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT verrecchiaelena biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT insalacoantonella biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT dagnalorenzo biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT jabermasenabdel biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT montindavide biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT emmigiacomo biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT ciarcialuisa biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT barneschisara biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT parronchipaola biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT ruscittipiero biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT maggiomariacristina biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT viapianaombretta biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT sotajurgen biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT gaggianocarla biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT giacomelliroberto biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT sicignanoludovicoluca biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT mannaraffaele biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT renierialessandra biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT lorizzocaterina biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT fredianibruno biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT rigantedonato biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork AT cantariniluca biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork |